Cipla challenges Novartis's 'evergreened' Onbrez patents and launches
This article was originally published in Scrip
Executive Summary
Novartis may find itself caught in another high-profile patent battle in India – this time concerning indacaterol (Onbrez /Arcapta), its drug for chronic obstructive pulmonary disease (COPD).